Chinese vaccine company Sinovac aims for 600 million dose capacity for COVID-19

Key Topics in this News Article:
News Snapshot:

China has at least five COVID-19 vaccine candidates running late stage clinical trials across more than a dozen countries. Sino Biopharmaceutical Ltd., a pharmaceutical conglomerate, bought a 15 per cent stake in Sinovac for an investment of USD 500 million. The funds will allow the company to ࢀœimprove our vaccine sales capabilities, expand in Asia markets, develop and access new technologies, and most importantly, accelerate our efforts to help combat the global pandemic,ࢀ Sinovac CEO Yin Weidong said in a statement. On Sunday, 1.2 million doses of its experimental vaccine arrived in Indonesia and are expected to be approved for…

  • This field is for validation purposes and should be left unchanged.
  • Newsletter to Your Inbox

    China intelligence delivered each week!

  • This field is hidden when viewing the form